Study Evaluating Inhibitor Specificity in Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer

Overview

This investigation will utilize a systematic determination of anti-FVIII antibody specificity in PTPs (\> 50 ED) with hemophilia A who have developed inhibitors in response to treatment with any FVIII product(s). A group of patients with hemophilia A, who have no evidence of current or prior FVIII inhibitor will be included for comparison. The objective of this study is to describe the patterns of antibodies and associated epitopes in the study population.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Conditions

Hemophilia A

Interventions

single blood drawPROCEDURE

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: · Patients with moderate or severe congenital hemophilia A, a current FVIII inhibitor, who have taken at least two different FVIII products during their lifetime. Exclusion Criteria: * Patients who have had an inhibitor prior to their current inhibitor. * Patients with immune disorders.

Locations (23)

Unnamed facility

Atlanta, Georgia, United States

Unnamed facility

Detroit, Michigan, United States

Outcomes

Primary Outcomes

Description of the patterns of antibodies and associated epitopes in a subset of

previously treated patients with hemophilia A.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.